Multiple Myeloma
From the Journals
First report of MM patient successfully treated for COVID-19 with tocilizumab
The patient presented with chest tightness and shortness of breath, indicating that symptoms of COVID-19 can be atypical in patients with...
Feature
Maintaining cancer care in the face of COVID-19
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect...
From the Journals
Multiple myeloma treatment produces a similar survival benefit in very elderly patients
From the Journals
Fracture risk for MM patients remains higher despite improvements in treatments, survival
Despite new treatment strategies there was no decreased fracture risk for multiple myeloma patients over time.
Conference Coverage
Stored CD34 cells for multiple myeloma patients largely unused
ORLANDO –
News
FDA approves new drug for relapsed/refractory multiple myeloma
From the Journals
New CAR T-cell therapy eliminates MM and tumor propagating cells without fratricide in lab study
CD229 CAR T cells are highly active in vitro and in vivo against multiple myeloma plasma cells, memory B cells, and MM-propagating cells.
From the Journals
CRISPR-engineered T cells may be safe for cancer, but do they work?
All three patients who received CRISPR-engineered T cells in a phase 1 trial experienced cancer progression but minimal toxicity.
From the Journals
Start of myeloma therapy may be delayed for women, minorities
Timeliness of treatment should be addressed urgently because of potential effects on disease morbidity, quality of life, and survival.
Conference Coverage
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.
Conference Coverage
D-RVd for frontline myeloma looks robust in GRIFFIN trial update
ORLANDO – The depth of response has improved over time, though further follow-up is needed to evaluate the durability of response and progression-...